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Vascular Alterations in a Murine Model of Acute Graft-Versus-Host Disease Are 
Associated With Decreased Serum Levels of Adiponectin and an Increased 
Activity and Vascular Expression of Indoleamine 2,3-Dioxygenase
Peter M. Schmid,* Abdellatif Bouazzaoui,† Karin Schmid,† Christoph M. Birner,* Christian Schach,* 
Lars S. Maier,* Ernst Holler,† and Dierk H. Endemann*
*Department of Internal Medicine 2–Cardiology, University Medical Center Regensburg, Regensburg, Germany
†Department of Internal Medicine 3–Hematology and Oncology, University Medical Center Regensburg, Regensburg, Germany
Graft-versus-host disease (GVHD) is the limiting complication after bone marrow transplantation (BMT), and 
its pathophysiology seems to be highly influenced by vascular factors. Our study aimed at elucidating possible 
mechanisms involved in vascular GVHD. For this purpose, we used a fully MHC-mismatched model of BALB/c 
mice conditioned according to two different intensity protocols with total body irradiation and transplantation 
of allogeneic (C57BL/6) or syngeneic bone marrow cells and splenocytes. Mesenteric resistance arteries were 
studied in a pressurized myograph. We also quantified the expression of indoleamine 2,3-dioxygenase (IDO), 
endothelial (eNOS), and inducible NO synthase (iNOS), as well as several pro- and anti-inflammatory cyto-
kines. We measured the serum levels of tryptophan (trp) and kynurenine (kyn), the kyn/trp ratio (KTR) as a 
marker of IDO activity, and adiponectin (APN). The myographic study showed a correlation of GVHD sever-
ity after allogeneic BMT with functional vessel alterations that started with increased vessel stress and ended 
in eccentric vessel remodeling, increased vessel strain, and endothelial dysfunction. These alterations were 
accompanied by increasing IDO activity and decreasing APN levels in the serum of allogeneic animals. The 
mRNA expression showed significantly elevated IDO, decreased eNOS, and elevation of most studied pro- and 
anti-inflammatory cytokines. Our study provides further data supporting the importance of vessel alterations in 
GVHD and is the first to show an association of vascular GVHD with hypoadiponectinemia and an increased 
activity and vascular expression of IDO. Whether there is also a causative involvement of these two factors in 
the development of GVHD needs to be further investigated.
Key words: Vascular graft-versus-host disease (GVHD); Indoleamine 2,3-dioxygenase (IDO); 
Adiponectin (APN); Cytokines
INTRODUCTION
Graft-versus-host disease (GVHD) is an often lethal 
complication and the main limitation on a wider use of 
allogeneic bone marrow transplantation (BMT) in the 
treatment of hematological disorders1. Over the past 
few years, the hypothesis of a vascular form of GVHD 
has emerged, which was based on different clinical and 
experimental findings in acute and chronic GVHD2,3. 
Recently, we could, for the first time, characterize func-
tional and structural vascular alterations in the early 
phase after allogeneic transplantation in an ex vivo 
setting4. In our animal model of acute GVHD, small 
vessel arteries of allogeneically transplanted BALB/c 
mice showed endothelial dysfunction and a geometry-
independent increase in vessel strain. Both findings 
were supported by electron microscopy, which showed 
severely injured endothelium and altered vessel walls. 
As a possible mechanism of endothelial dysfunction, we 
found dysregulated expression of endothelial (eNOS) 
and inducible nitric oxide (NO) synthase (iNOS) in the 
vasculature. Our data further substantiated the hypothesis 
of vascular GVHD and the assumption that vasoprotec-
tive therapy may ameliorate systemic GVHD. Therefore, 
the underlying mechanisms of vascular injury need to be 
further elucidated. Endothelial function and integrity are 
influenced by many different factors5. Great importance 
in this context is attached to all kinds of inflammatory 
processes. On the one hand, inflammation acutely and 
chronically alters endothelial function; on the other hand, 
the endothelium is a main regulator of inflammation in 
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turn. GVHD is characterized by an immense inflamma-
tory response, but factors affecting endothelial function 
and causing vascular injury are not yet understood.
Therefore, we developed two different intensity trans-
plantation protocols, both of them causing GVHD, but 
only the more intense generating vascular injury and 
endothelial dysfunction. In this model, we investigated 
potential pathophysiological mechanisms of vascular 
injury by analyzing factors that possibly link endothe-
lial function to inflammation in acute GVHD, namely, 
indoleamine 2,3-dioxygenase (IDO), adiponectin (APN), 
and NO. Furthermore, vascular GVHD should further be 
characterized by quantifying the expression of several 
pro- and anti-inflammatory cytokines.
MATERIALS AND METHODS
Experimental Bone Marrow Transplantation
All animal experiments had been approved by the 
local institutional animal committee of the University 
of Regensburg and were conducted in accordance with 
German animal protection laws. Transplantations were 
carried out according to a well-established protocol of 
our laboratory as recently described elsewhere4,6. In 
brief, female C57BL/6N (H-2b) and BALB/c (H-2d) mice 
purchased from Charles River Laboratories (Sulzbach, 
Germany) were transplanted at an age of 11 to 12 weeks. 
On the day of BMT, BALB/c recipient mice were con-
ditioned using a linear accelerator with 150 cGy/min. 
After that, the mice received a mixture of bone marrow 
cells and splenocytes from either syngeneic (BALB/c, 
synTx) or allogeneic (C57BL/6, alloTx) donors. The 
irradiation dose and the count of transplanted bone mar-
row cells and splenocytes were diversified according to 
two different intensity protocols as shown in Table 1 
[low- intensity protocol (LIP) and high-intensity proto-
col (HIP)]. Animals were housed for 4 weeks after trans-
plantation and then euthanized for further investigation 
of their mesenteric arteries. Of the eight allogeneically 
transplanted animals in each group, one from the LIP 
and three from the HIP group died during the 4 weeks. 
Of all syngeneically transplanted animals, only one in the 
HIP group died (Table 1). Untreated animals served as 
controls to detect possible effects of irradiation and trans-
plantation procedures (n = 5, ctrl).
Clinical GVHD Score and Serum Samples
Clinical GVHD scores were assessed weekly after trans-
plantation by a standard scoring system that incorporated 
five clinical parameters: weight loss, posture (hunching), 
mobility, fur texture, and skin integrity7. Each parameter 
was graded between 0 and 2 followed by the calculation 
of the cumulative score for each mouse. Blood samples 
were obtained immediately after euthanasia in week +4. 
We measured tryptophan (trp), kynurenine (kyn), and the 
kyn/trp ratio (KTR) (Immundiagnostik AG, Bensheim, 
Germany) as a marker of IDO activity as well as  levels 
of APN in serum (R&D Systems, Minneapolis, MN, 
USA) via enzyme-linked immunosorbent assay (ELISA) 
according to the respective manufacturer’s instruction.
Myographic Study
After euthanasia, the mesenteric vasculature was dis-
sected for preparation of the small resistance arteries. 
The myographic study was then conducted according to 
protocols well established in our laboratory4,8. In brief, 
one second-order branch of the superior mesenteric artery 
was prepared in each animal, mounted onto a pressur-
ized myograph (111 P; Danish Myo Technology, Aarhus, 
Denmark), and perfused with oxygenated 37°C KREBS 
solution (95% O2, 5% CO2) (pH 7.4) containing NaCl 
(118 mmol/L), KH2PO4 (1.18 mmol/L), KCl (4.7 mmol/L), 
MgSO4 (1.18 mmol/L), CaCl2 (2.5 mmol/L), D- glucose (5.5 
mmol/L), NaHCO3 (25 mmol/L), and EDTA (0.026 mmol/L). 
First, the active vasodilatory properties of the resistance 
arteries were investigated. After precontraction with nor-
epinephrine (NE; 10−5 mol/L) endothelium- dependent 
vasodilation was assessed by addition of acetylcholine 
(ACh) in increasing concentrations (10−10–10−4 mol/L) 
to the vessels in the chamber of the myograph. For 
evaluation of endothelium-independent vasodilation, 
the direct NO donor sodium nitroprusside (SNP) (10−9–
10−2 mol/L) was used (all reagents for the myographic 
study were from AXXORA GmbH, Lörrach, Germany). 
Therefore, at each concentration of the given agent, 
the vessels lumen diameter and wall thickness were 
determined after 5 min of incubation. Thereafter, the 
intraluminal pressure of the vessels was equilibrated 
at 45 mmHg, their media thickness and lumen diam-
eter were measured, and parameters of vessel geometry 
Table 1. Conditions of the Two Transplantation Protocols and Numbers of Transplanted Animals
Irradiation 
Dose (Gy) BMC (×106) SC (×106) alloTx (n) synTx (n)
Low-intensity protocol Tx (LIP) 8 2 1 8/7 5/5
High-intensity protocol Tx (HIP) 9 2.5 2 8/5 5/4
Abbreviations: Gy, gray; BMC, transplanted bone marrow cells; SC, transplanted splenocytes; alloTx, number of allo-
geneically transplanted and surviving animals after 4 weeks; synTx, number of syngeneically transplanted and surviving 
animals after 4 weeks.
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were calculated [media/lumen ratio and cross-sectional 
area (CSA)]. Finally, myogenic tone was inactivated 
by calcium depletion through incubation with Ca2+-free 
KREBS solution for 30 min. Intravascular pressure was 
raised from 3 to 10, 20, 30, and 40 mmHg and then 
in 20 mmHg steps up to 140 mmHg to assess pas-
sive mechanical properties (circumferential strain and 
stress). All vessel measurements for vasodilatory and 
mechanical properties were performed at three points 
along the vessel with the use of a calibrated video sys-
tem, and the mean was calculated.
mRNA Expression in Mesenteric Resistance Arteries
The expression of IDO, eNOS, iNOS, tumor necro-
sis factor-a (TNF-a), interferon-g (IFN-g),  interleukin-1a 
(IL-1a), IL-1b, IL-2, IL-4, IL-6, IL-10, and IL-11 in small 
arteries was measured using real-time reverse transcrip-
tion polymerase chain reaction (RT-PCR) as described 
previously4,8. Total RNA from mesenteric arteries of 
the second branch was extracted using an RNeasy kit 
(Qiagen, Hilden, Germany). Total RNA (1 µg) was used 
in the reverse transcription reaction (reagents were from 
Promega, Mannheim, Germany). Real-time RT-PCR 
was detected with the ABIPrism 7900 TaqMan (Applied 
Biosystems, Foster City, CA, USA) using b-actin as 
housekeeping gene for normalization. TaqMan probes 
(Table 2) were purchased from Applied Biosystems and 
Eurofins (Regensburg, Germany). After measuring each 
animal in triplicate, the mean was calculated.
Data Analysis
All data are shown as mean ± standard error of the 
mean (SEM). A value of p < 0.05 was considered signifi-
cant. Groups were compared using one-way analysis of 
variance (ANOVA) with the Holm–Šidák as a post hoc 
test. CSA of the media (Table 3), vessel vasodilation 
to ACh, and SNP circumferential strain, stress, and the 
strain/stress relation were calculated as described previ-
ously4. Curves for vasodilatory and mechanical vessel 
properties were compared with two-way ANOVA for 
repeated measurements with the Holm–Šidák method as 
a post hoc test.
RESULTS
Body Weight and Clinical GVHD Score
Figure 1 shows the biometric animal data over the 
course of the animal experiment. The baseline body 
weight (week 1) in all groups was between 19 and 21 g. 
The weight of control animals had slightly increased 
over the 4-week experiment. In contrast, in the first week 
after BMT, body weight had significantly declined in all 
other groups. HIP allogeneic animals showed the highest 
weight loss (−26.4%). In the weeks after transplantation, 
syngeneically transplanted animals recovered and were 
even heavier in week +4 than at baseline [synTx(LIP): 
+5.3%, synTx(HIP): +6.9%]. Allogeneically transplanted 
animals had also shown a slight weight gain over the first 
2 weeks after BMT but clearly lost weight in week +4, 
resulting in significantly reduced body weight at the end 
of the experiment [alloTx(LIP): −9.9%, alloTx(HIP): 
−24.6%] compared to all other animal groups. This find-
ing was accompanied by the development of GVHD after 
allogeneic BMT as objectified by the clinical GVHD 
score. In week +4, HIP allogeneic animals reached a 
significantly higher score (6 ± 0.3) than LIP allogeneic 
animals (3.9 ± 0.7), indicating more severe GVHD after 
HIP transplantation. The scores of allogeneic animals 
were significantly higher than those for syngeneically 
transplanted animals [synTx(LIP): 1.4 ± 0.1, synTx(HIP): 
2.2 ± 1.1].
Vasodilatory Vessel Properties
The vasodilatory response of mesenteric resistance 
arteries to increasing concentrations of ACh and SNP 
Table 2. Primer Sequences Used for Gene Expression Analysis
Gene Forward Primer Reverse Primer Company
IDO CCGGTCACGAATGTGGAACT AGCTGCCCGTTCTCAATCAG Eurofins
eNOS Mm00435217_m1 Applied biosystems
iNOS Mm00440502_m1 Applied biosystems
TNF-a AGGCACTCCCCCAAAAGATG TTTGCTACGACGTGGGCTAC Eurofins
IFN-g CTTCAGCAACAGCAAGGCG AGCGACTCCTTTTCCGCTTC Eurofins
IL-1a Mm00439620_m1 Applied biosystems
IL-1b Mm00434228_m1 Applied biosystems
IL-2 TTTTACTTGCCCAAGCAGGC GAAAGTCCACCACAGTTGCTG Eurofins
IL-4 CAAACGTCCTCACAGCAACG GGCATCGAAAAGCCCGAAAG Eurofins
IL-6 Mm00446190_m1 Applied biosystems
IL-10 AAGGGTTACTTGGGTTGCCA GAAATCGATGACAGCGCCTC Eurofins
IL-11 Mm00434162_m1 Applied biosystems
b-Actin Mm04394036_g1 Applied biosystems
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was tested ex vivo (Fig. 2). Since ACh causes NO release 
from the endothelium, which in turn provokes relaxation 
of smooth muscle cells in the vessel wall, ACh-induced 
vasodilation depends on an intact endothelium. Usually, 
we expect that high concentrations of ACh (10−4 mol/L) 
are able to nearly completely reverse the precontraction 
of resistance arteries with NE (10−5 mol/L). However, in 
our experiments, endothelium-dependent vasodilation 
(Fig. 2A) was significantly decreased in HIP allogeneic 
animals, which indicated endothelial dysfunction. In con-
trast, LIP allogeneic animals did not show any endothe-
lial dysfunction. In all other transplantation groups, the 
response to small doses of ACh (10−8 and 10−7 mol/L) was 
even more pronounced than in the control group, but vaso-
dilation at higher concentrations remained unchanged. 
Maximum vasodilation reached at 10−4 mol/L of ACh 
was 83.3 ± 4.0% for ctrl, 93.0 ± 3.1% for alloTx(LIP), 
96.7 ± 1.5% for synTx(LIP), 55.1 ± 5.2% for alloTx(HIP), 
and 96.7 ± 3.8% for synTx(HIP). Furthermore, we 
assessed the vasodilatory response to SNP (Fig. 2B). SNP 
acts as a direct NO donor, and therefore its vasodilatory 
effect does not depend on endothelium as a NO producer, 
but only on working smooth muscle cells. Endothelium-
independent vasodilation in the investigated groups did 
not show any differences, indicating normal function of 
the smooth muscle cells.
Table 3. Geometry of Mesenteric Arteries at 45 mmHg Intraluminal Pressure
Parameters Control alloTx(LIP) synTx(LIP) alloTx(HIP) synTx(HIP) p Value
Media thickness (µm) 9.9 ± 0.2 11.3 ± 0.5 11.3 ± 0.2 9.9 ± 0.7 9.6 ± 0.3 0.018
Lumen diameter (µm) 175 ± 2 232 ± 15* 209 ± 5 222 ± 9† 173 ± 8 <0.001
Media/lumen ratio 5.6 ± 0.1 4.9 ± 0.2 5.4 ± 0.1 4.4 ± 0.2* 5.6 ± 0.3 0.011
CSA (µm²) 5,782 ± 192 8,714 ± 780* 7,814 ± 729 7,234 ± 749 5,529 ± 289 0.001
Abbreviations: CSA, cross-sectional area of media; alloTx, allogeneic transplantation; synTx, syngeneic transplantation. The p 
values for one-way ANOVA comparing all animal groups.
Media thickness: Holm–Šidák without any significant differences between the individual groups.
Lumen diameter: Holm–Šidák *p < 0.01 versus synTx(HIP) and control; †p < 0.05 versus synTx(HIP) and control.
Media/lumen ratio: Holm–Šidák *p < 0.01 versus control, p < 0.05 versus synTx(LIP) and synTx(HIP).
CSA: Holm–Šidák *p < 0.01 versus synTx(HIP), p < 0.05 versus control.
Figure 1. Biometric animal data. (A) Percentage changes in body weight between controls and allogeneically and syngeneically trans-
planted animals. Significant loss of weight in allogeneically transplanted animals after BMT. Week +1: One-way ANOVA (p < 0.001) 
with Holm–Šidák: *p < 0.001 versus all other groups; #p < 0.001 versus alloTx(LIP), p < 0.01 versus synTx(HIP), p < 0.05 versus 
synTx(LIP). Week +2: One-way ANOVA (p = 0.005) with Holm–Šidák: *p < 0.01 versus ctrl. Week +3: One-way ANOVA (p = 0.002) 
with Holm–Šidák: *p < 0.01 versus ctrl. Week +4: One-way ANOVA (p < 0.001) with Holm–Šidák: *p < 0.001 versus ctrl, synTx(LIP), 
and synTx(HIP), p < 0.05 versus alloTx(LIP); #p < 0.001 versus ctrl, p < 0.05 versus synTx(LIP) and synTx(HIP). (B) Clinical GVHD 
score. Development of severe GVHD after BMT in HIP allogeneic animals. Week +1: One-way ANOVA (p < 0.001) with Holm–Šidák: 
*p < 0.001 versus synTx(LIP) and synTx(HIP), p < 0.05 versus alloTx(LIP); #p < 0.05 versus synTx(LIP). Week +2: One-way ANOVA 
(p = 0.002) with Holm–Šidák: *p < 0.01 versus synTx(LIP), p < 0.05 versus synTx(HIP). Week +3: One-way ANOVA (p = 0.01) with 
Holm–Šidák: *p < 0.05 versus synTx(LIP). Week +4: One-way ANOVA (p < 0.001) with Holm–Šidák: *p < 0.001 versus synTx(LIP) 
and synTx(HIP), p < 0.05 versus alloTx(LIP); #p < 0.05 versus synTx(LIP).
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Morphological and Mechanical Vessel Properties
The morphological data of mesenteric vessels assessed 
at an intraluminal pressure of 45 mmHg are shown in 
Table 3. The media thickness of the vessels significantly 
differed between the animal groups, and HIP syngeneic ani-
mals tended to have the thinnest media. Lumen diameters 
were highest in allogeneically transplanted animals, which 
resulted in a significant lower media and lumen ratio and 
thus eccentric vascular remodeling in HIP allogeneic ani-
mals. LIP allogeneic animals only showed a trend toward 
eccentric remodeling, but this trend was not significant. 
Figure 3 depicts circumferential strain and stress as well as 
the strain/stress relationship as further passive mechanical 
vessel properties. Strain (Fig. 3A) represents vessel com-
pliance. Only HIP allogeneic animals showed a significant 
increase between 40 and 140 mmHg. In contrast, vessels of 
LIP allogeneic animals showed no increase in compliance, 
at best a slight trend in comparison to LIP syngeneic and 
control animals. Circumferential stress (Fig. 3B) matched 
the wall tension of vessels and was significantly elevated 
after allogeneic transplantation in both groups. Thereby, 
the strain/ stress relationship (Fig. 3C) clearly indicated 
higher vessel strain at the same stress levels with a right 
shift of the curve for HIP transplanted animals.
Serum levels of IDO Metabolites, KTR, and APN
IDO is the rate-limiting enzyme for the catabolism 
of trp to kyn. Therefore, the KTR reflects IDO activity. 
Levels of trp (Fig. 4A) were significantly reduced in HIP 
allogeneic animals and only tended to be lower in LIP 
allogeneic animals [ctrl: 2,467 ± 112 µmol/L, alloTx(LIP): 
2,034± 114 µmol/L, synTx(LIP): 2,392 ± 185 µmol/L, 
alloTx(HIP): 1,639 ± 98 µmol/L, synTx(HIP): 2,263 ± 
181 µmol/L]. Concomitantly, levels of kyn (Fig. 4B) 
were significantly elevated in both allogeneic animal 
groups [ctrl: 0.37 ± 0.02 µmol/L, alloTx(LIP): 2.83 ± 
0.42 µmol/L, synTx(LIP): 0.88 ± 0.1 µmol/L, alloTx(HIP): 
2.67 ± 0.2 µmol/L, synTx(HIP): 0.8 ± 0.11 µmol/L]. This 
elevation significantly increased KTR and thus IDO 
activity in allogeneically transplanted animals in compar-
ison to syngeneic and control animals (Fig. 4C). Among 
allogeneic animals, HIP animals also had a significantly 
higher KTR than LIP animals [ctrl: 164 ± 12 µmol/mol, 
alloTx(LIP): 1,095 ± 161 µmol/mol, synTx(LIP): 368 ± 
25 µmol/mol, alloTx(HIP): 1,557 ± 103 µmol/mol, 
synTx(HIP): 349 ± 30 µmol/mol]. Levels of APN (Fig. 4D) 
were significantly reduced after allogeneic transplanta-
tion. Again, levels were even significantly lower in HIP 
allogeneic animals than in the LIP allogeneic group 
[ctrl: 010.8 ± 0.2 mg ml, alloTx(LIP): 9.5 ± 0.4 mg/ml, 
synTx(LIP): 12.9 ± 0.3 mg/ml, alloTx(HIP): 6.2 ± 0.6 mg/
ml, synTx(HIP): 12.5 ± 0.6 mg/ml].
mRNA Expression in Mesenteric Resistance Arteries
Table 4 summarizes the relative expression of IDO, 
NO synthases, and investigated cytokines. Consistent 
Figure 2. Active vasodilatory properties of mesenteric resistance arteries. (A) Endothelium-dependent vasodilatory response to ace-
tylcholine. Vasodilatory response to acetylcholine is significantly reduced in vessels of HIP transplanted animals. Two-way ANOVA 
for repeated measurements (p < 0.001) with Holm–Šidák: *p < 0.05 versus alloTx(LIP) and synTx(LIP); #p < 0.01 versus synTx(LIP) 
and synTx(HIP), p < 0.05 versus alloTx(LIP); §p < 0.001 versus synTx(HIP), p < 0.01 versus alloTx(LIP) and synTx(LIP); $p < 0.01 
versus alloTx(LIP), synTx(LIP), and synTx(HIP); &p < 0.001 versus alloTx(LIP), p < 0.01 versus synTx(LIP) and synTx(HIP). 
(B) Endothelium-independent vasodilatory response to sodium nitroprusside. Vasodilatory response to sodium nitroprusside is unaffected 
after BMT. Two-way ANOVA for repeated measurements: p = 0.553.
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with the increased IDO activity in the serum, IDO expres-
sion in the vessel wall was significantly elevated in 
allogeneic animals compared to syngeneic and control 
animals. In contrast, eNOS expression was significantly 
reduced in allogeneic compared to syngeneic animals, 
whereas iNOS expression did not significantly dif-
fer between the groups. The cytokines TNF-a, IFN-g, 
IL-1a, IL-1b, IL-2, and IL-10 showed significantly 
higher expression after allogeneic BMT than after syn-
geneic BMT. The expression of IL-4 only tended to be 
higher after allogeneic BMT. IL-6 levels were only sig-
nificantly elevated in HIP allogeneic animals and tended 
to be higher in LIP allogeneic animals. No differences 
could be observed for IL-11.
DISCUSSION
New Insights Into Vascular Function in GVHD
Recently4, we could for the first time directly inves-
tigate vascular alterations of mesenteric resistance arter-
ies in GVHD in an ex vivo setting. In our present study, 
we investigated functional vessel alterations after BMT 
conducted according to two different intensity pro-
tocols (Table 1). As objectified by the clinical GVHD 
score and the weight loss during the animal experiment, 
Figure 4. Serum levels of IDO metabolites, KTR, and APN. (A) Levels of tryptophan. Tryptophan levels are significantly decreased 
after allogeneic transplantation. One-way ANOVA (p < 0.001) with Holm–Šidák: *p < 0.01 versus ctrl and synTx(LIP), p < 0.05 ver-
sus synTx(HIP). (B) Levels of kynurenine. Kynurenine levels are significantly increased after allogeneic transplantation. One-way 
ANOVA (p < 0.001) with Holm–Šidák: *p < 0.001 versus ctrl, synTx(LIP), and synTx(HIP); #p < 0.001 versus ctrl, synTx(LIP), and 
synTx(HIP). (C) Kynurenine/tryptophan ratio (KTR). KTR as a marker of IDO activity is significantly increased after allogeneic trans-
plantation. One-way ANOVA (p < 0.001) with Holm–Šidák: *p < 0.001 versus ctrl, synTx(LIP), and synTx(HIP); #p < 0.001 versus 
ctrl, synTx(LIP), and synTx(HIP), p < 0.01 versus alloTx(LIP). (D) Levels of APN. Levels of APN are significantly decreased after 
allogeneic transplantation. One-way ANOVA (p < 0.001) with Holm–Šidák: *p < 0.01 versus synTx(LIP) and synTx(HIP); #p < 0.001 
versus ctrl, alloTx(LIP), synTx(LIP), and synTx(HIP).
Delivered by Ingenta to: Universitaet Regensburg
IP: 132.199.144.70 On: Tue, 17 Jan 2017 15:21:56
Article(s) and/or figure(s) cannot be used for resale. Please use proper citation format when citing this article including the DOI,
publisher reference, volume number and page location.
2058 SCHMID ET AL.
allogeneic animals of the HIP group developed more 
severe GVHD than animals of the LIP group (Fig. 1). 
Interestingly, the HIP group matched the transplanta-
tion group of our previous study. For these animals, our 
present study confirmed endothelial dysfunction (Fig. 2) 
and increased vessel compliance after allogeneic trans-
plantation  (Fig. 3A). New findings were slight changes 
in vessel geometry resulting in a reduced media/lumen 
ratio in terms of eccentric vessel remodeling (Table 3) 
and also significantly increased vessel stress compared 
to syngeneic and control animals (Fig. 3B). In contrast, 
allogeneically transplanted animals from the LIP group 
did not develop endothelial dysfunction (Fig. 2) or 
increased vessel compliance (Fig. 3A) and only showed 
a trend toward eccentric vessel remodeling (Table 3). 
However, these animals also had increased vessel stress 
 (Fig. 3). Our present results therefore suggest that vessel 
alterations in acute GVHD correlate with the severity of 
GVHD. Increased vessel stress is already present at the 
early stages of GVHD. In progressive GVHD, vessels 
develop eccentric remodeling and, finally, increased ves-
sel compliance and endothelial dysfunction. Since the 
main difference between both transplantation protocols 
consists in the higher number of transplanted spleno-
cytes in the HIP group, which represent alloreactive cells 
in mice, our results further emphasize the hypothesis of 
a vascular GVHD.
New Potential Mechanisms Involved in 
Vascular Dysfunction and GVHD
A main target of our study was to further elucidate 
possible mechanisms leading to the observed vessel 
alterations and particularly to endothelial dysfunction. 
Since GVHD is characterized by immense inflammatory 
processes, we further investigated factors of endothelial 
function also involved in inflammation, such as IDO, 
APN, and NO.
IDO has been known to be induced in different models 
of inflammation for over 30 years9,10. It is the first and 
rate-limiting enzyme of the kyn pathway, converting trp 
to kyn. IDO plays a remarkable role in immunomodula-
tion in many inflammatory diseases and tumorigenesis11,12 
and is predominantly activated by IFN-g13,14, but also by 
lipopolysaccharides15, TNF-a16, IL-6, and IL-1b11. As 
reviewed by Murakami et al.11, the immunosuppressive 
effect of IDO results from inhibited T cell prolifera-
tion by local depletion of trp, the apoptotic properties 
of trp metabolites such as 3-hydroxykynurenine (3-HK) 
and 3-hydroxyanthranilic acid (3-HAA) on T cells, and 
the ability of IDO to activate mature regulatory T cells 
Table 4. Relative Expression of IDO, NO Synthases, and Cytokines in Mesenteric Resistance Arteries
Control alloTx(LIP) synTx(LIP) alloTx(HIP) synTx(HIP) p Value
IDO 0.08 ± 0.02 1.19 ± 0.16* 0.32 ± 0.11 1.0 ± 0.21† 0.20 ± 0.04 <0.001
eNOS 1.41 ± 0.29 0.91 ± 0.06* 2.13 ± 0.49 0.98 ± 0.09* 2.23 ± 0.22 0.002
iNOS 0.68 ± 0.17 2.33 ± 0.86 0.67 ± 0.20 1.84 ± 0.32 1.27 ± 0.62 0.088
TNF-a 0.01 ± 0.003 5.21 ± 2.18* 0.12 ± 0.003 4.95 ± 1.27* 0.01 ± 0.003 0.003
IFN-g 0.02 ± 0.01 0.70 ± 0.10* 0.03 ± 0.01 0.74 ± 0.18† 0.03 ± 0.01 <0.001
IL-1a 0.10 ± 0.01 3.50 ± 0.64* 0.31 ± 0.10 2.80 ± 0.43† 0.18 ± 0.06 <0.001
IL-1b 0.20 ± 0.05 4.23 ± 0.84* 0.68 ± 0.11 5.66 ± 1.15† 0.46 ± 0.08 <0.001
IL-2 0.06 ± 0.02 5.45 ± 1.30* 0.09 ± 0.01 4.75 ± 1.08* 0.09 ± 0.04 0.002
IL-4 2.06 ± 0.56 3.70 ± 0.05 1.70 ± 0.07 3.24 ± 0.64 1.29 ± 0.80 0.053
IL-6 0.17 ± 0.04 1.49 ± 0.22 0.75 ± 0.07 2.60 ± 0.50† 1.00 ± 0.24 <0.001
IL-10 0.04 ± 0.01 2.15 ± 0.59* 0.27 ± 0.25 3.26 ± 0.42† 0.10 ± 0.04 <0.001
IL-11 0.65 ± 0.08 1.12 ± 0.37 1.02 ± 0.78 2.57 ± 1.05 1.95 ± 0.08 0.410
Abbreviations: IDO, indoleamine 2,3-dioxygenase; eNOS, endothelial NO synthase; iNOS, inducible NO syn-
thase. The p values for one-way ANOVA comparing all animal groups.
IDO: Holm–Šidák *p < 0.001 versus control, p < 0.01 versus synTx(LIP) and synTx(HIP); †p < 0.01 versus control, 
p < 0.05 versus synTx/LIP) and synTx(HIP).
eNOS: Holm–Šidák *p < 0.05 versus synTx(LIP) and synTx(HIP).
TNF-a: Holm–Šidák *p < 0.05 versus control, synTx(LIP), and synTx(HIP).
IFN-g: Holm–Šidák *p < 0.01 versus control, p < 0.05 versus synTx(LIP) and synTx(HIP); †p < 0.01 versus control 
and synTx(HIP), p < 0.05 versus synTx(LIP).
IL-1a: Holm–Šidák *p < 0.01 versus and synTx(HIP), p < 0.05 versus synTx(LIP); †p < 0.05 versus control, 
synTx(LIP), and synTx(HIP).
IL-1b: Holm–Šidák *p < 0.01 versus control and synTx(HIP), p < 0.05 versus synTx; †p < 0.05 versus control, 
synTx(LIP), and synTx(HIP).
IL-2: Holm–Šidák *p < 0.05 versus control, synTx(LIP), and synTx(HIP).
IL-6: Holm–Šidák †p < 0.001 versus control, p < 0.01 versus synTx(LIP), p < 0.05 versus synTx(HIP).
IL-10: Holm–Šidák *p < 0.01 versus control and synTx(HIP), p < 0.05 versus synTx(LIP); †p < 0.001 versus ctrl, 
synTx(LIP), and synTx(HIP).
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(Tregs) and to convert naive T cells to Tregs. In animal 
models of GVHD, IDO activation is suggested to amelio-
rate disease severity and reduce mortality17–19. In GVHD 
in humans, kyn urine levels as a marker of IDO activity 
correlate with disease severity20, and IDO is upregulated 
in gut GVHD in humans21. However, a high expression of 
IDO in intestinal mucosal mononuclear cells and a low 
expression in endothelial cells were associated with a 
favorable outcome in gut GVHD22. This finding suggests 
a specific endothelial effect of IDO, which was affirmed 
by actual research showing functional effects of endothe-
lial IDO in inflammation23,24. Other studies reported vaso-
protective effects of 3-HAA25,26 and an apoptotic impact 
of 3-HK on endothelial cells27. These results suggest a 
paradoxical role of IDO in GVHD with favorable effects 
in immune cells by immunosuppressive effects and harm-
ful actions in the endothelium by inducing apoptosis and 
microvascular dysfunction. In our study, we found a sig-
nificantly elevated KTR as a marker of IDO activation 
in allogeneic animals with even significantly higher  levels 
in the HIP than in the LIP group (Fig. 4C). Here IDO 
activity correlated with GVHD severity and the devel-
opment of endothelial dysfunction. We could also show 
that IDO is expressed higher locally in the vessels of 
allogeneic animals than in those of syngeneic and con-
trol animals (Table 4). We concluded that, in our animal 
model, IDO activation may play an important role in ves-
sel damage and endothelial dysfunction. We assumed 
that a shift from vasoprotective trp metabolites (3-HAA) 
toward metabolites with apoptotic effects in endothelial 
cells might be responsible for vascular alterations. This 
assumption could also explain the paradoxical effect of 
IDO in immune and endothelial cells on clinical outcome, 
further highlighting the importance of vascular function 
in GVHD. Further studies, for example, in IDO knock-
out animals, after a pharmacological blockade of IDO or 
in an IDO overexpression model, are required to further 
substantiate this hypothesis and the effects of trp metabo-
lites on vascular function.
Another factor involved in endothelial function and 
inflammatory processes is APN. We and several other 
authors have shown that APN can induce vasodilation in 
small resistance arteries in rats and that hypoadiponectine-
mia is associated with endothelial dysfunction in a model 
of diabetes mellitus type 28,28–30. The reduced levels of 
APN observed in obesity and its comorbidities are usu-
ally explained with a low-grade inflammatory process 
in adipose tissue itself 31–33. In contrast, APN levels are 
reported to be elevated in classic chronic inflammatory 
processes, a paradox that is not yet well understood34,35. 
To our knowledge, only a single report is available 
showing that patients with chronic GVHD have signifi-
cantly increased APN levels that correlate with disease 
severity36. This study provides the first data of APN in 
acute GVHD, showing a significantly reduced level after 
allogeneic BMT with even significantly lower levels in 
HIP than in LIP allogeneic animals (Fig. 4D). With its 
vasoprotective and anti-inflammatory properties in mind, 
we propose that hypoadiponectinemia is a possible addi-
tional factor in the development of endothelial dysfunc-
tion in acute GVHD.
As already stated in our recent study4, NO produced 
by eNOS and iNOS also plays an important role in 
endothelial function and inflammation. We assumed that 
reduced eNOS and increased iNOS expression could 
contribute to endothelial dysfunction and apoptosis. In 
fact, we could confirm our former results, showing that 
eNOS—which provides low doses of NO essential for 
 endothelial  function37—is significantly downregulated in 
both allogeneic animal groups in comparison to syngeneic 
animals. A higher expression level of iNOS in allogeneic 
animals producing NO in cytotoxic concentrations38 could 
not be verified in mesenteric arteries (Table 4). However, 
we measured the expression of NO synthases, but not 
NO levels, directly. Such measurements are methodi-
cally extremely complex, so that elevated NO levels, as 
described in GVHD39,40, cannot be reliably excluded in 
mesenteric arteries. Thus, dysregulation of NO homeosta-
sis with reduced expression of eNOS is a further possible 
mechanism linking GVHD to endothelial dysfunction.
Cytokine Pattern in Mesenteric Arteries  
After Allogeneic BMT
A further aim of our study was to characterize 
inflammatory processes in the vessel walls by analyz-
ing the expression of the different cytokines involved in 
GVHD. According to the established pathophysiological 
model of acute GVHD, an immense release of different 
 cytokines—often referred to as a “cytokine storm”—is 
essential to trigger and coordinate the attack of graft T 
cells on host tissue1,41. To our knowledge, we now report 
here for the first time an expression pattern of several rel-
evant cytokines in vessels of acute GVHD. We could find 
significantly elevated expression levels for IL-1a, IL-1b, 
IL-2, IL-6, TNF-a, and IFN-g in allogeneic animals of 
both the HIP and LIP groups (Table 4), which resembles 
the pathophysiological model of GVHD. Besides their 
function in coordinating the immune response, many 
cytokines are also assumed to have a direct effect on the 
endothelium. For TNF-a and IFN-g, some studies have 
shown that they can induce endothelial cell apoptosis 
on their own or sensitize the apoptotic effects of other 
factors42,43. Also, IL-1b and IL-6 seem to cause endothelial 
dysfunction44,45. However, not only proinflammatory Th1 
cytokines are involved in the pathophysiology of acute 
GVHD, but anti-inflammatory Th2 cytokines such as IL-4 
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and IL-10 also play an important role46,47. IL-4 is known 
to be upregulated in GVHD48 and may beneficially influ-
ence the severity of GVHD49,50. In contrast, other studies 
have suggested a harmful role of IL-4 in GVHD51,52. In 
our study, IL-4 tended to be expressed higher in alloge-
neically transplanted animals, but this finding slightly 
missed the significance level. Data exist that IL-4 has 
proinflammatory and proatherogenic effects in vascular 
tissues by decreasing NO bioavailability through nicotin-
amide adenine dinucleotide phosphate (NADPH) oxidase 
activation53, which may also contribute to endothelial 
dysfunction. IL-10 is generally considered to have anti-
inflammatory effects54, and a high production of IL-10 
before transplantation correlates with subsequent low 
incidence of GVHD55. However, IL-10 administration 
had a detrimental outcome in GVHD56, and elevated 
IL-10 levels were associated with a poor prognosis in 
GVHD, possibly due to functional immunodeficiency57. 
Accordingly, other studies have shown that administration 
of IL-10 might reduce GVHD58. In our study, we found 
that IL-10 is significantly overexpressed after allogeneic 
BMT in both transplantation groups, which is in line 
with elevated IL-10 levels in severe GVHD. A benefi-
cial effect on endothelial function has been described for 
IL-1059,60, which acts vasoprotectively61,62 and regulates 
the endothelial barrier function63,64. However, these favor-
able effects of IL-10 are not noticeable, at least not in HIP 
allogeneic animals that show endothelial dysfunction and 
increased vessel compliance. Whether IL-10 expression 
contributes to intact endothelial function in LIP alloge-
neic animals remains unclear. For IL-11, a cytokine with 
pleiotropic effects in multiple tissues65, no significant dif-
ferences were found after BMT.
The expression pattern of the different cytokines 
present in small vessel arteries resembles that of typi-
cal GVHD known from other tissues. This fact further 
emphasizes the hypothesis of a self-contained form of 
vascular GVHD. Additionally, TNF-a, IFN-g, IL-1b, 
IL-6, and IL-4 can directly or indirectly mediate endothe-
lial cell apoptosis or endothelial dysfunction and pose 
another mechanism of vascular damage.
CONCLUSIONS
Our present study could confirm vascular injury after 
allogeneic BMT and show that vascular alterations develop 
in correlation with the severity of GVHD. Thereby, we 
are the first to show an association of APN and IDO with 
the observed vascular changes. Since APN and different 
trp metabolites are known to have vascular effects, it is 
important to further investigate whether these factors are 
also causative for the development of vascular GVHD. 
The presented cytokine expression pattern from mesen-
teric arteries in acute GVHD is unique and resembles that 
of typical GVHD from other tissues. This finding strongly 
supports the hypothesis of a self- contained vascular form 
of GVHD. In conclusion, our study has generated new 
topics for future research targeting the pathophysiology 
and the treatment of vascular GVHD. These results may 
allow a better understanding of GVHD to ameliorate vas-
cular damage and avoid potential systemic GVHD.
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